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Cameron S. Carter1 and Paul Ashwood2,3*
Abstract
Background: Over the past 30 years, evidence has been accumulating for an immunological component to
schizophrenia etiology, including genetic links to the major histocompatibility complex, microglia activation, and
dysregulated cytokine profiles. However, the degree of similarity in cytokine profiles for schizophrenia and bipolar
disorder, as well as the relationship between cytokine levels and brain structure, is less well understood.
Methods: To address this, we recruited 69 first-episode schizophrenia-spectrum patients, 16 first-episode bipolar
patients with psychotic features, and 53 healthy controls, from the UC Davis EDAPT clinic. Blood plasma was
collected and analyzed for all participants with a subset of participants that also underwent structural MRI on a 1.5T
GE scanner.
Results: Plasma levels of interleukin (IL)-1β, IL-2, IL-6, and interferon (IFN)-γ were elevated in schizophrenia patients
compared to those in controls. Patients with bipolar disorder had elevated plasma IL-10 levels compared to controls,
and the two patient groups did not differ significantly on any immunological measure. Percent whole-brain gray
matter was inversely correlated with IFN-γ and IL-12 levels in patients with schizophrenia, with a trend relationship
between IFN-γ and IL-12 and prefrontal cortical thickness. Furthermore, psychotic symptoms were positively related
to IL-1β levels in individuals with schizophrenia.
Conclusions: These data suggest a partially overlapping pattern of elevated blood cytokine levels in patients with
first-episode schizophrenia and bipolar disorder with psychotic features. Furthermore, our findings suggest that
elevated pro-inflammatory cytokines may be particularly involved in schizophrenia etiology, given evidence of
cytokine-related decreases in total gray matter.
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Background
Schizophrenia is a complex neurodevelopmental dis-
order that affects approximately 1% of the population
and appears to be caused by the combination of genetic
risk factors and environmental insults [1, 2]. While
dopaminergic hyperfunction in the limbic system and
dopaminergic hypofunction in the frontal cortex are im-
plicated in the pathophysiology of schizophrenia, many
aspects of the etiology of schizophrenia remain unknown
[3]. There is a growing awareness that immune dysfunc-
tion may play a role in neurodevelopmental disorders
such as schizophrenia and bipolar disorder, which share
some genetic and phenotypic features [4–6]. There is
rapidly growing evidence for a strong link between
schizophrenia and genes that regulate both immune
function and brain development located in the major
histocompatibility complex (MHC) region on
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chromosome 6 [7–9]. Immune mediators such as cyto-
kines and chemokines can modulate neural development
[10, 11] and synapse plasticity [12], which may contrib-
ute to cognitive, behavioral, and brain structure abnor-
malities seen in psychotic disorders.
A significant number of studies have attempted to de-
termine whether or not there are differential cytokine
profiles in individuals with schizophrenia. A quantitative
review of 62 studies that included 2298 individuals with
schizophrenia and 1858 controls found that plasma/sera
levels were increased for interleukin (IL)-1 receptor an-
tagonist, soluble IL-2 receptor, and IL-6 in individuals
with schizophrenia [13]. In a second meta-analysis,
where 40 studies were assessed, data pointed to the pres-
ence of a subset of elevated cytokines in schizophrenia,
with potential state markers during acute exacerbations
and first-episode psychosis that included increased in-
flammatory cytokines IL-1β and IL-6, and the regulatory
cytokine transforming growth factor-β (TGF-β). Import-
antly, these cytokine levels were normalized after ther-
apy [14]. Potential trait markers that remained elevated
following antipsychotic treatment such as elevated
IL-12, interferon-γ (IFN-γ), and tumor necrosis factor-α
(TNF-α) were also identified [14]. Taken together, both
studies clearly show that cytokine levels are altered in
the plasma/sera of individuals with schizophrenia.
A similar search for a unique cytokine profile in bipolar
disorder has revealed a largely overlapping immune profile
with schizophrenia. A meta-analysis of 30 studies that in-
cluded 1351 individuals with bipolar disorder and 1248
controls found that plasma/sera levels were elevated for
IL-6, TNF-α, soluble IL-2 receptor, IL-4, IL-10, IL-1 recep-
tor antagonist, and soluble TNF receptor-1 [15]. Notably,
IL-4 and IL-10 elevations were highly significant in this
meta-analysis, but are less frequently identified in patients
with schizophrenia. In contrast, IFN-γ elevations are fre-
quently noted in patients with schizophrenia, but less so
in patients with bipolar disorder. Several studies have dir-
ectly compared plasma cytokine levels between these two
groups, generally focusing on a small number of candidate
cytokines. Kunz et al. [16] examined three cytokines (IL-6,
IL-10 and TNF-α) in a chronic sample and found elevated
IL-6 in schizophrenia, but not bipolar disorder, while both
groups showed elevated IL-10 compared to controls, and
there were no significant differences between groups for
TNF-α. In contrast, IL-6 was not different between groups
in a sample of 125 bipolar, 186 schizophrenia, and 244
control participants [17]. Rather, soluble TNF receptor 1
and von Willebrand factor were increased in both disor-
ders compared to controls. A recent meta-analysis of 18
schizophrenia, 16 bipolar disorder, and 12 major depres-
sive disorder studies revealed significant elevations of
IL-6, TNF-α, IL-1 receptor antagonist, and soluble IL-2 re-
ceptor in acute episodes of all groups compared to
controls. Furthermore, in chronic patients, IL-6, soluble
IL-2 receptor, and IL-1β were similarly elevated in schizo-
phrenia and bipolar groups compared to controls [18].
Taken together, these data suggest that the affective and
non-affective psychoses may exhibit generally similar cyto-
kine profiles (i.e., elevations of IL-6, IL-1β, TNF-α, soluble
IL-2 receptor), with some focal differences (i.e., IL-4 and
IL-10 in bipolar participants).
Because of the potential biological and therapeutic im-
portance of any overlap in cytokines in schizophrenia
and bipolar disorder with psychotic features, it is im-
perative to analyze cytokine profiles indicated by these
meta-analyses in individuals with first-onset schizophre-
nia and directly compare to patient groups with bipolar
disorder with psychotic features and age-matched
healthy controls. In addition, the relationship between
changes in plasma cytokine profiles and changes in brain
structure and symptomatology should be assessed to
provide insight into their potential role in the patho-
physiology of psychotic disorders, rather than as
non-specific peripheral markers of stress responses asso-
ciated with having a mental illness. Several groups have
reported such links. IL-6 gene expression in blood leu-
kocytes, for example, was associated with decreased hip-
pocampal volume in patients with schizophrenia [19]. In
addition, an aggregate measure of pro-inflammatory
cytokine levels (i.e., summed z-transformed IL-2, IFN-γ,
and TNF-α) was negatively associated with prefrontal
cortical thickness, particularly in individuals at risk for
and who eventually developed a psychotic disorder [20].
To provide a more granular view of how particular cyto-
kines relate to brain structure and symptomatology in
patients with first-episode schizophrenia and bipolar dis-
order with psychotic features, we focused on a narrow
range of inflammatory markers implicated in previous
meta-analyses [14, 15], which included pro-inflammatory
cytokines IL-1β, IL-2, IL-6, IL-12, IFN-γ, and TNF-α and
the anti-inflammatory cytokines IL-4 and IL-10. The
first goal of this study was to investigate any differences
in cytokine levels in plasma between individuals with
first-episode schizophrenia, first-episode bipolar dis-
order with psychotic features, and healthy controls. The
second goal of the study was to reveal any associations
between changes in cytokine levels and brain structure.
Given previous reports [14, 15], we anticipated a largely
overlapping pattern of pro-inflammatory cytokine ele-
vation in both patient groups compared to controls.
Furthermore, we predicted that pro-inflammatory cyto-
kines would be related to both global (i.e., whole-brain
gray matter) and local (i.e., prefrontal cortical thick-
ness) brain structural abnormalities. Finally, we ex-
pected that higher levels of pro-inflammatory cytokines
would be associated with increasing psychotic
symptomatology.
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Methods
Demographic and clinical characteristics
Sixty-nine first-episode schizophrenia-spectrum patients
(60 schizophrenia, 8 schizoaffective, and 1 schizophreni-
form), 16 first-episode bipolar disorder I patients with
psychotic features, and 53 healthy control subjects be-
tween 13 and 32 years of age were recruited for the
present study. Table 1 outlines demographic and clinical
status at the time of testing. First-episode psychosis par-
ticipants were outpatients within 1 year of onset of
psychotic symptoms. All participants were assessed
using the Structured Clinical Interview for the
DSM-IV-TR (SCID)-I/P [21]. Clinical interviews were
conducted by clinicians trained to high degree of reli-
ability (kappa> 0.80; range 0.80–1.0). First-episode par-
ticipants were followed longitudinally and diagnoses
were confirmed 12 months after ascertainment. Clinical
ratings were collected in the patient sample using the
Scale for the Assessment of Negative Symptoms (SANS;
[22]), Scale for the Assessment of Positive Symptoms
(SAPS; [23]), Brief Psychiatric Rating Scale (BPRS; [24]),
and Global Assessment of Functioning (GAF; [25]). Dur-
ation of illness was defined as the number of days be-
tween the structural MRI and first threshold psychotic
symptom presentation, which was based on all available
information (i.e., parent/subject report, medical records).
The majority of patients with schizophrenia and bipolar
disorder were taking atypical antipsychotic medication,
with only 15 individuals not taking antipsychotics (10
schizophrenia, 5 bipolar). Antipsychotic dose was con-
verted to chlorpromazine (CPZ) equivalent form. Both
retrospective and current antipsychotic doses were col-
lected to facilitate analyses of both current medication
level and cumulative exposure to antipsychotics (calcu-
lated as number of days on a given dose times dose for
those days). Dose history and current medication dose
were obtained via self-report and verified with caregivers
and notes in the medical record when possible. Exclu-
sion criteria for all groups included Wechsler Abbrevi-
ated Scale of Intelligence (WASI) IQ score below 70,
alcohol or drug dependence or abuse within 3 months
before testing, positive urine toxicology screen for illicit
drugs at time of testing, use of anti-inflammatory medi-
cation, presence of significant general medical condition
related to immune compromise, prior head trauma
worse than a Grade I concussion, or contraindication to
MRI scanning. Controls were excluded for the following
additional criteria: any lifetime diagnosis of an axis I or
axis II disorder or any first-degree relatives with a psych-
otic disorder. After a complete description of the study
to the subjects, written informed consent was obtained.
The study was approved by the University of California,
Davis Institutional Review Board, and subjects were
compensated for their participation.
Table 1 Demographic and clinical characteristics of the sample
Control (n = 53) Schizophrenia (n = 69) Bipolar (n = 16)
Age: mean (SD)
[minimum, maximum]
19.5 (3.3)
[13, 32]
19.9 (3.5)
[13, 30]
21.4 (3.4)
[14, 27]
Gender (% male/female) 64/36 88/12 75/25
Subject education: mean (SD) 12.7 (2.9) 12.0 (2.2) 12.7 (1.7)
Parental education: mean (SD) 14.1 (3.2) 13.9 (2.8) 14.8 (2.6)
SANS: mean (SD) – 10.3 (3.6) 7.5 (4.9)
SAPS: mean (SD) – 6.2 (3.7) 2.9 (3.3)
BPRS: mean (SD) – 42.04 (8.2) 38.1 (8.0)
GAF: mean (SD) – 41.46 (8.5) 46.50 (13.0)
WASI: mean (SD) 115.71 (10.0) 100.49 (13.2) 100.13 (11.2)
Duration of illness: mean number of days (SD) – 319.25 (243.0) 226.00 (204.5)
Antipsychotic dose (CPZ mg): mean (SD) – 252.1 (192.2) 271.2 (202.7)
Antipsychotic medication: (n) –
Aripiprazole
Asenapine
Haloperidol
Olanzapine
Quetiapine
Risperidone
Ziprasidone
More than one atypical
Unmedicated
14
1
1
7
3
27
1
5
10
1
0
0
2
1
5
1
1
5
SD standard deviation, SANS Scale for the Assessment of Negative Symptoms, SAPS Scale for the Assessment of Positive Symptoms, BPRS Brief Psychiatric Rating
Scale, GAF Global Assessment of Functioning, WASI Wechler Abbreviated Scale of Intelligence, CPZ Chlorpromazine equivalent dose
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Participant demographic and clinical information is pre-
sented in Table 1. Participants with schizophrenia did not
differ in age from controls (t(120) = .64, p = 0.522) or from
participants with bipolar disorder with psychotic features
(t(83) = 1.60, p = 0.114). However, participants with bipolar
disorder were significantly older than controls (t(67) = 2.04,
p = 0.045). The sample was comprised of significantly more
males in the schizophrenia group compared to the control
group (Fisher’s exact test p = 0.002), while the bipolar sam-
ple did not differ from either controls (p = 0.550) or schizo-
phrenia patients (p = 0.227) in terms of gender. The groups
did not differ significantly on participant education levels
(all pairwise t tests p > 0.20) or parental education (all
pairwise t test p > 0.29). However, the control group scored
significantly higher on the WASI compared with schizo-
phrenia (t(117) = 6.90, p < 0.001) and bipolar disorder pa-
tients (t(65) = 5.15, p < 0.001). Schizophrenia and bipolar
patients did not differ on WASI (t(80) = .10, p = 0.922),
GAF (t(82) = 1.48, p = .156), duration of illness (t(70) = 1.29,
p = 0.203), or BPRS scores (t(69) = 1.63, p = 0.108). Schizo-
phrenia patients scored higher on the SANS (t(71) = 2.42,
p = 0.018) and SAPS (t(67) = 3.04, p = 0.003) compared to
individuals with bipolar disorder.
Twenty-six of the individuals with schizophrenia were on
monotherapy antipsychotic medication, while 22 individuals
were taking an antipsychotic with 1 additional medication
and 11 were taking 2 or more additional medications. Other
medications included anticholinergics (n = 5), mood stabi-
lizers (n = 12), antidepressants (n= 18), anxiolytics (n= 12),
stimulants (n = 2), and sleep aids (n= 2). Of the 10 individ-
uals with schizophrenia not taking antipsychotics, 4 were
taking antidepressants and 6 were taking no medication
whatsoever. Four of the individuals with bipolar disorder
with psychotic features were on monotherapy antipsychotic
medication, while five individuals were taking an anti-
psychotic with one additional medication and two individ-
uals were taking two or more additional medications. Other
medications in this group included anticholinergics (n = 1),
mood stabilizers (n= 5), antidepressants (n= 3), anxiolytics
(n= 1), and sleep aids (n= 1). Of the five individuals with bi-
polar disorder with psychotic features not taking antipsy-
chotics, three were taking mood stabilizers and two were
taking no medications whatsoever. Fisher’s exact test re-
vealed significantly higher mood stabilizer use in the bipolar
disorder group compared to schizophrenia (p= 0.01), with
no significant differences in use of other medications (all
p > 0.374). There were also no group differences in fre-
quency of antipsychotic medication use (Fisher’s exact test
p= 0.146) or average dose (t(68) = 0.263, p= 0.68).
Immunological procedures
Peripheral blood was collected from each subject in
acid-citrate dextrose Vacutainers (BD Biosciences; San
Jose, Ca). Blood was processed to obtain plasma by
centrifugation at 2100 rpm for 10 min, and plasma was
harvested, aliquoted and stored at − 80 °C until cytokine
analysis. Plasma was assessed for protein levels of IL-1β,
IL-2, IL-4, IL-6, IL-10, IL-12p70, IFN-γ, and TNF-α
using a Multi-Plex high-sensitivity bead set (Millipore,
Saint Charles, MO; Product Number HSCY-
MAG60SPMX13). Samples were run at one time accord-
ing to the manufacturer’s protocol, with one sample
tested per subject. Briefly, 25 μL of sample was incu-
bated with antibody-coupled fluorescent beads and then
washed and incubated with biotinylated detection anti-
bodies followed by streptavidin–phycoerythrin. The
beads were then analyzed using flow-based Luminex™
100 suspension array system (Bio-Plex 200; Bio-Rad
Laboratories, Inc.). Standard curves were generated by
Bio-plex Manager software to determine unknown sam-
ple concentration, and reference cytokines were pro-
vided by the manufacturer in the kit. The minimum
detectable amount for the cytokines were as follows: IL-1β
0.06 pg/mL, IL-2 0.26 pg/mL, IL-4 0.42 pg/mL, IL-6
0.2 pg/mL, IL-10 0.48 pg/mL, IL-12p70 0.34 pg/mL,
IFN-γ 0.18 pg/mL, and TNF-α 0.07 pg/mL. Unknown
sample concentrations that were below the limit of
detection for a particular cytokine were excluded from all
subsequent analyses.
Structural image procedures
A subset of participants underwent brain imaging (30
schizophrenia, 29 control, and 10 bipolar). Spoiled gradi-
ent recalled (SPGR) images were collected on a 1.5T GE
Signa scanner using the following parameters: TR =
9 msec, TE = 2 msec, flip angle = 15°, field of view =
22 cm, 124 1.5-mm axial slices, and 0.86-mm2 in-plane
resolution. Images were processed with the Freesurfer
software package (version 4.3, http://surfer.nmr.mgh.har-
vard.edu [26, 27] using the following processing stream).
First, images underwent standard Freesurfer processing,
including alignment to Talairach space, brain extraction,
intensity normalization, segmentation, surface gener-
ation, and parcellation. After this initial automatic pro-
cessing, software developed at the UC Davis Imaging
Research Center was used to identify potentially
problematic regions in each image. These regions were
identified using information from Freesurfer output (i.e.,
Freesurfer’s list of “defect” locations that the software
attempted to correct) as well as image intensity consid-
erations (i.e., high intensity voxels occurring immediately
adjacent to lower intensity voxels). A custom script was
then used to sequentially present these regions to the
viewer, who was blind to group membership, for possible
manual editing. The primary purpose of this additional
procedure was to offer a systematic way of ensuring that
regions posing particular difficulty to Freesurfer’s auto-
mated pipeline would be viewed and corrected if
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necessary. This procedure was implemented in addition
to a whole-brain slice-by-slice examination in which er-
rors in brain extraction, image intensity, segmentation,
and surface generation were corrected manually accord-
ing to Freesurfer documentation. Surface renderings of
white and gray matter surfaces were then viewed for de-
fects and corrected manually before final processing was
completed. A final visual inspection after all manual
intervention was completed confirmed that each image
had been appropriately corrected.
Cortical thickness measurements were obtained for
each vertex and were mapped on a common spherical
coordinate system. Left and right middle frontal gyrus
regions of interest were extracted a priori from each
subject to evaluate the relationship between cytokine
levels and cortical thickness in a region repeatedly iden-
tified as impacted in psychotic disorders. Volumetric
measurements were computed using Freesurfer’s seg-
mentation procedure and extracted for whole-brain gray
matter and whole-brain white matter to provide a gross
metric of brain structure. These volumetric measures
were adjusted for each individual subject’s intracranial
volume in order to provide a percent gray and percent
white matter value that takes into account individual
variation in head size.
Statistical procedures
All statistical analyses were performed in SPSS Statistics
Version 22 (IBM, Armonk, NY, USA). All tests were
two-tailed with alpha set at p < 0.05. The majority of
immunological data was significantly skewed and was
analyzed using nonparametric tests. Specifically,
Kruskal-Wallis tests were implemented comparing all
three groups, followed by pairwise Mann–Whitney U
tests. Spearman’s Rho was implemented for correlation
analyses. In order to evaluate the potential impact of
gender imbalances on cytokine levels, supplementary
analyses were performed comparing cytokine levels be-
tween the schizophrenia and control group. Based on
procedures described by Conover and Iman [28], cyto-
kine data were rank transformed across groups and sep-
arate ANCOVAs were performed for each cytokine
including gender as a covariate. Similarly, in order to ac-
count for the influence of age and gender on the rela-
tionship between cytokine levels and brain structure,
supplementary nonparametric partial correlations were
performed using Spearman’s Rho [29], controlling for
age and gender within each group. To account for mul-
tiple comparisons, the Benjamini–Hochberg procedure
[30] was used to maintain a false discovery rate of p <
0.05 for the eight cytokines examined within each ana-
lysis (i.e., cytokine levels and cytokine-brain structure
correlations). Correlations between cytokine and clinical
measures were considered exploratory with alpha set at
p < 0.05. Group comparisons on measures that violated
sphericity assumptions were adjusted using Green-
house–Geisser [31].
Results
Immunological results
Examining cytokines across all three groups (see Fig. 1 for
boxplots), Kruskal-Wallis tests revealed significant overall
group differences for IL-2 (H(2) = 15.93, p < 0.001) and IL-10
(H(2) = 10.53, p= 0.005) after correcting for multiple com-
parisons. In comparison to controls, schizophrenia patients
had higher levels of IL-2 (U= 1573.5, p < 0.001) and also the
inflammatory cytokines IL-1β (U= 1565.5, p= 0.011), IL-6
(U= 1975.5, p= 0.018), and IFN-γ (U= 2076.0, p= 0.018)
(Fig. 1). There was also a trend for increased IL-12 levels in
schizophrenia but this did not reach statistical significance
following correction for multiple comparisons. In addition,
in comparison to controls, levels of the regulatory cytokine
IL-10 were elevated in bipolar patients with psychotic fea-
tures (U= 587, p= 0.002). The two patient groups did not
differ significantly on any immunological measure following
correction for multiple comparisons, although there was a
trend for higher IL-10 levels in bipolar disorder compared to
schizophrenia participants (U= 648, p= 0.063). Taken to-
gether, these results show a strong pro-inflammatory pheno-
type in the serum of individuals with schizophrenia
compared to controls, with bipolar participants characterized
by nonsignificant pro-inflammatory elevations and uniquely
elevated IL-10.
Given the presence of a significant gender imbalance in
the control versus schizophrenia group, supplementary
analyses were conducted using rank transformed ANCOVA
and including gender as a covariate. Including gender as a
covariate on the ranked data had a relatively minor impact
on the results: IL-1β (F1,96 = 6.62, p = 0.012), IL-2 (F1,90 =
15.14, p < 0.001), IL-6 (F1,110 = 5.59, p = 0.020), and IFN-γ
(F1,113 = 4.17, p = 0.043). However, IL-6 and IFN-γ narrowly
miss the cutoff threshold for Benjamini-Hochberg FDR
correction.
Relationship of immune measures with structural and
clinical measures
A trend inverse correlation was identified between percent
whole-brain gray matter and IL-12 (rs = −.502, p = 0.009)
in the control group, after correcting for multiple compar-
isons. Schizophrenia patients showed a significant inverse
relationship between percent whole-brain gray matter and
IFN-γ (rs = −.515, p = 0.004). Following correction for
multiple comparisons, no correlations of cytokines with
cortical thickness were observed. In schizophrenia pa-
tients, there was a trend towards an inverse correlation for
left middle frontal gyrus thickness and IFN-γ (rs = −.424,
p = 0.024) but this did not reach significance following
correction for multiple comparisons. No significant
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correlations were identified in the bipolar participants,
although there was a trend for an inverse relationship
between percent whole-brain white matter and IL-1β
(rs = −.624, p = 0.054).
Given that some participant characteristics may influ-
ence the relationship between cytokine levels and brain
structure, follow-up analyses were performed using non-
parametric Spearman’s Rho partial correlations control-
ling for age and gender within each group. After
controlling for age and gender, the control group did not
show any significant relationships between brain struc-
ture and cytokine levels. The relationship between IFN-γ
and percent whole-brain gray matter remained signifi-
cant (rs = −.567, p = 0.003) in the schizophrenia group,
with the additional finding of a significant negative rela-
tionship between IL-12 and percent whole-brain gray
matter (rs = −.508, p = 0.008). Controlling for age and
gender did not alter findings for individuals with bipolar
disorder with psychotic features. Additional file 1: Table
S1 presents cytokine-structure correlations without co-
varying for age and gender, while Additional file 1: Table
S2 presents cytokine–structure correlations controlling
for these variables.
In terms of clinical symptomatology, a significant positive
relationship was identified between SAPS scores and IL-1β
(rs = .367, p = 0.012) in the schizophrenia group. In patients
with bipolar disorder, a significant inverse relationship be-
tween SANS scores and IL-2 (rs = −.660, p = 0.020) was
identified. Notably, correlations with symptomatology
(Additional file 1: Table S3) were exploratory and would
not survive correction for multiple comparisons.
Relationship of immune measures and antipsychotic
medication
Given that antipsychotic medications may alter immune
profiles [32], we examined the relationship of anti-
psychotic medication and cytokine levels. Ten of 69 indi-
viduals with schizophrenia and 5 of 16 individuals with
bipolar disorder were not taking antipsychotic medica-
tion at the time of the blood draw. Mann–Whitney U
tests between patients taking medications and those who
were unmedicated at the time of blood draw revealed no
effect of current antipsychotic medication on cytokine
levels in the schizophrenia sample (all p > 0.126) but did
show higher IL-2 levels in unmedicated patients with bi-
polar disorder compared to medicated patients with
Fig. 1 Tested cytokine levels across groups. Boxplots representing cytokine levels in each group across all eight cytokines tested. The number of
subjects analyzed for each cytokine is recorded below each respective boxplot graph. The dark lines within each box represent the median, top
and bottom borders of the box represent the third and first quartiles, and top and bottom whiskers represent the highest case within 1.5 times
the interquartile range. Asterisks reflect p < .05 significance after false discovery rate correction using the Benjamini-Hochberg procedure. For ease
of visualization, extreme values outside this range are excluded from these plots but are reported in Additional file 1: Table S4 in the Supplement
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bipolar disorder (U = 0, p = 0.003). However, given the
very small number of unmedicated patients with schizo-
phrenia (n = 10) and bipolar disorder with psychotic fea-
tures (n = 5), these results should be interpreted with
caution. To further explore possible relationships be-
tween medication and cytokine levels, correlations were
first computed between cytokine level and current anti-
psychotic medication dose (Additional file 1: Table S3).
In patients with schizophrenia, a significant positive
association was identified between antipsychotic dose
and both IL-2 (rs = .307, p = 0.040) and IL-10 (rs = .273,
p = 0.036). Additionally, cumulative exposure to
antipsychotic medication over the lifespan (dose times
duration) was significantly related to IL-6 (rs = .271,
p = 0.041) and IL-12 (rs = .274, p = 0.036) in patients
with schizophrenia. Given that cumulative anti-
psychotic exposure was highly correlated with dur-
ation of illness (rs = .490, p < 0.001), one concern
was that antipsychotic relationships to IL-6 and
IL-12 may simply reflect alterations associated with
the length of the illness. Notably, IL-6 levels were signifi-
cantly associated with duration of illness (rs = .368, p =
0.006), although IL-12 levels were not (rs = .044, p =
0.748). This pattern of results suggests that while the rela-
tionship between cumulative antipsychotic exposure and
IL-6 may be confounded by duration of illness, higher
IL-12 values in individuals with greater exposure to
antipsychotics may be interpreted with greater confi-
dence as relating to medication effects. Secondary
analyses using nonparametric Spearman partial corre-
lations covarying for duration of illness agree with
this interpretation given that IL-6 levels are no longer sig-
nificantly related to antipsychotic exposure (rs = .122, p =
0.430) while IL-12 remains significant (rs = .290, p =
0.037). Neither current dose nor cumulative exposure
metrics showed a relationship with cytokine levels in
individuals with bipolar disorder. Finally, it should be
noted that analyses of medication effects were
exploratory and would not survive correction for
multiple comparisons.
Discussion
In order to start to test the hypothesis that immune acti-
vation may play a role in the etiology of schizophrenia
and/or bipolar disorder or in their continued patho-
physiology, we measured peripheral cytokine protein
levels and correlated those changes with clinical symp-
toms and brain structure in individuals with schizophre-
nia, bipolar disorder with psychotic features, and healthy
controls. Our findings are consistent with this hypoth-
esis since cytokines are indeed elevated in the plasma of
both schizophrenia and bipolar disorder compared to
controls and those elevations correlate with the severity
of clinical symptoms and decreases in whole-brain gray
matter volume, at least in schizophrenia. Compared to
controls, there were differences in these measures be-
tween bipolar disorder and schizophrenia, suggesting
that the immune contribution to these disorders is over-
lapping but with distinct features. Together, our results
are consistent with the growing body of work implicat-
ing ongoing immune dysregulation in the pathophysi-
ology of psychotic disorders.
Cytokines mediate signals between the immune and
nervous system and can help shape both neuronal re-
sponses and subsequent behaviors as well as brain
growth early in development. Examining cytokines that
regulate neuroimmune communication in health and
disease can provide insight into the potential role of the
immune response in individuals with schizophrenia.
The pro-inflammatory cytokines IL-1β, IL-6, and
IFN-γ were increased in first-episode schizophrenia
compared with controls, similar to previous findings
described in meta-analytic studies [14]. Because these
cytokines are acute phase cytokines that promote in-
flammation, these results indicate a pro-inflammatory
state in the periphery in schizophrenia that could be the
result of and/or contribute to the ongoing the disease
process. We also found that IL-2 was increased in
schizophrenia, again consistent with previous reports
[33, 34]. Notably, soluble IL-2 receptor (sIL-2R) levels
have been reported by others to be consistently in-
creased in schizophrenia [14]. As sIL-2R can bind IL-2
with an affinity similar to that of cell membrane IL-2 re-
ceptor, it is possible that sIL-2R acts in an immunosup-
pressive manner to block IL-2 interacting with its
receptors, suggesting that the “net” or biological effect of
elevated IL-2 found in our study would be neutral. To-
gether, these results are consistent with the possibility
that pro-inflammatory cytokines contribute to the on-
going pathophysiology of schizophrenia.
While median levels of IL-6, IFN-γ, and IL-12 in the bi-
polar disorder group were near or above levels in the
schizophrenia group, none were significantly different com-
pared to either group. However, the anti-inflammatory
cytokine IL-10 was only significantly elevated in
first-episode bipolar disorder, consistent with a previous
meta-analysis [15]. These elevations in IL-10 could be indi-
cative of immunosuppression, or it could reflect a compen-
satory response to the elevations in the pro-inflammatory
cytokines.
Changes in peripheral cytokine levels in young adults
with first-episode psychosis likely reflect ongoing symp-
tomology and brain structural changes associated with
the disease process. Although the cause of these elevated
cytokines is unknown, it is possible that they reflect on-
going immune dysregulation that started in gestation.
Maternal infection during gestation is a risk factor for
schizophrenia [35], and direct injection of inflammatory
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cytokines into a pregnant mouse results in structural
brain abnormalities as well as behavioral and cognitive
abnormalities in the offspring [1, 2]. Consistent with this
idea, offspring from mouse models of maternal immune
activation exhibit prominent immune changes that per-
sist into adulthood including changes in macrophage ac-
tivation, decreased regulatory T cells, and increased T
helper 17 (TH17) cells that produce IL-17, as well as
changes in levels of several pro- and anti-inflammatory
cytokines within different regions of the brain [36–40].
In addition, ongoing activation of myeloid cells and pro-
duction of inflammatory cytokines were directly related
to behavioral outcomes in the MIA model [36]. In
humans, recent studies have shown that a heightened
immune response during pregnancy can modulate and
influence the developing immune system leading to
changes in the offspring that last into adulthood [41].
Thus, immune dysfunction noted in some individuals
with schizophrenia, including altered plasma cytokine
levels reported here, could be related to prenatal ex-
posures in a manner suggested by the MIA preclinical
model.
Correlations between elevations in some of these cyto-
kines and brain structure suggest that at least some of
the cytokines may contribute to the pathophysiology in
schizophrenia. The strongest association was an inverse
relationship between pro-inflammatory cytokines IFN-γ
and IL-12 and percent whole-brain gray matter in indi-
viduals with schizophrenia. These results are consistent
with data showing an inverse relationship between an-
other pro-inflammatory cytokine, IL-6, and hippocampal
gray matter volume in healthy middle-aged adults [42].
Although one cannot directly compare protein found in
the plasma and mRNA cytokine expression levels in
cells, it is interesting to note that IL-6 gene expression
in blood leukocytes is inversely associated with hippo-
campal volume in patients with schizophrenia [19]. In-
creased IL-1β mRNA levels in leukocytes in patients
with schizophrenia have also been linked to decreased
Broca’s area volume and poorer verbal fluency [43]. Fi-
nally, Dieset et al. [44] evaluated seven peripheral endo-
thelial markers in patients with bipolar disorder and
schizophrenia and found the most significant relation-
ship between von Willebrand factor and basal ganglia
size. Thus, it is intriguing to evaluate whether an
increase in pro-inflammatory cytokine levels in the per-
iphery may provide a way to measure immune dysregu-
lation in individuals that might translate to differences
in the CNS. Future studies will need to determine the
relationship between peripheral cytokine levels and ex-
pression levels of IL-6, IL-8, and to some extent IL-1β,
which have been shown to be elevated in the DLPFC in
postmortem tissue from patients with schizophrenia
[45]. Other markers of inflammation, such as cellular
activation of microglia, have also been found in patients
with schizophrenia, particularly in the hippocampus and
whole-brain gray matter [46, 47]. Whether this activa-
tion is associated with increased pro-inflammatory cyto-
kine production needs further testing. In contrast to
schizophrenia, the lack of a significant relationship be-
tween cytokine elevations and brain structure in the bi-
polar subjects may indicate that inflammation is not a
key factor in bipolar disorder. However, there was a
trend for an inverse relationship between IL-1β and
whole-brain white matter, which suggests the small
sample size may have limited our ability to detect
these effects.
The relationship between cytokine levels measured in
blood plasma and brain structure has not been ad-
equately studied, particularly in first-episode samples.
Our results suggest that pro-inflammatory cytokine ele-
vations, particularly IFN-γ and IL-12, may be linked to
whole-brain gray matter volume reductions. Given that
several cytokines, including IFN-γ, may alter the perme-
ability of the blood brain barrier [48], elevations in
pro-inflammatory cytokines in the periphery could influ-
ence brain development and induce structural changes.
IFN-γ activation of inflammatory T cells and
antigen-presenting cells along with the regulation of
MHC class 2 genes could result in a tonically active
immune response, which in turn could alter neuronal
repair and growth, causing decreases in gray matter
volume.
In terms of symptomatology, elevated IL-1β in the
schizophrenia sample was linked to increased positive
symptoms on the SAPS. Because patients experience fluc-
tuations in psychotic symptoms during the course of their
disease, this finding suggests that increased IL-1β may
fluctuate over time in synchrony with symptom exacerba-
tions. While longitudinal studies are needed to truly evalu-
ate this hypothesis, the theory is consistent with findings
that IL-1β as well as IL-6 and TGF-β may reflect state
markers for schizophrenia [14]. In contrast, IL-2 was
negatively correlated with negative symptoms (SANS) in
bipolar participants, which is more difficult to interpret.
Paradoxically, Igue and colleagues [49] identified an in-
verse relationship whereby increased levels of sIL-2R were
related to a decrease in positive symptoms for individuals
with schizophrenia treated with quetiapine. The finding of
increased IL-2 levels relating to lower levels of negative
symptoms suggests that immune imbalances relate to a
wide spectrum of symptomatology.
Changes in cytokine levels were also associated with
antipsychotic medication, such that higher IL-2 and IL-10
levels were related to higher antipsychotic doses at the
time of the scan in the schizophrenia sample. In addition,
higher cumulative exposure to antipsychotics was associ-
ated with higher IL-6 and IL-12 levels, although IL-6 was
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no longer significant after controlling for duration of ill-
ness. Increased IL-10 has been linked to atypical anti-
psychotic treatment in mouse models exposed to
lipopolysaccharide (LPS) and polyinsinic-polycytidylic acid
(Poly I:C) [50], as well as in vitro studies using Poly I:C
stimulated blood samples from patients with schizophre-
nia [51]. Stimulated macrophages and peripheral blood
mononuclear cells treated with a range of antipsychotics
have also shown increased release of IL-10 [52, 53]. These
findings are consistent with many recent clinical studies in
schizophrenia and bipolar disorder suggesting an increase
in anti-inflammatory cytokines associated with anti-
psychotic treatment, which may play a protective or
ameliorative role in treatment. For example, Sobis and col-
leagues [54] treated 17 chronic schizophrenia patients
with aripiprazole over 1 month and identified significant
reductions in a range of pro-inflammatory cytokines with
a sole increase in IL-10. In contrast, a study conducted in
antipsychotic-naïve first-episode schizophrenia patients
identified decreased IL-10 and IL-1RA associated with
6 weeks of atypical antipsychotic treatment [55]. Further-
more, a recent meta-analysis of 23 in vivo studies (762
subjects) using pre-post designs concluded that anti-
psychotic treatment increases IL-2R and IL-12 levels, with
decreases in IL-1β and IFN-γ [56]. While our findings of
increases in IL-12 are consistent with this meta-analysis,
we did not see antipsychotic-related decreases in IL-1β or
IFN-γ. Ultimately, individual studies evaluating anti-
psychotic effects on cytokine levels are mixed, which may
be due to the large variability in methodologies used,
including exposure in animal models versus humans,
stimulated blood samples from healthy versus psychiatric
groups, specificity of antipsychotic tested, sera tested in
longitudinal versus cross-sectional designs, and sample
differences in terms of chronicity. While recent
meta-analyses have moved the field forward, more work
needs to be done to truly unravel the relationship of anti-
psychotic medications with cytokine levels.
Although we tried to account for potentially con-
founding factors in the current study, several limitations
must be considered. The relatively small sample size of
bipolar subjects may have limited our ability to detect
the full extent of cytokine alterations in this sample, par-
ticularly with respect to schizophrenia subjects given
that both groups showed cytokine elevations. While the
patient groups did not differ in terms of antipsychotic
exposure, the use of mood stabilizers was more frequent
in the bipolar group. Since mood stabilizer medication
has been linked to lower pro-inflammatory cytokine
levels (i.e., IL-6) (for review see [57]), this may have fur-
ther normalized cytokine levels in the bipolar group. In
bipolar participants, only IL-10 levels survived correc-
tion for multiple comparisons, while other cytokines that
have been consistently implicated in the disorder were
not detected (i.e., IL-4 and TNF-α). In addition, the
schizophrenia and control groups were imperfectly
matched, with a higher percentage of males in the
schizophrenia group. Supplementary analyses covarying
for gender suggested a minimal impact of gender on the
results, although such a small group of females may not
be fully representative of that patient group. Similarly,
while the bipolar group was slightly older, age and gen-
der were included as a covariate in cytokine-structure
relationships in an attempt to statistically adjust for this
difference. It should also be reiterated that evaluation of
relationships between cytokine levels and both anti-
psychotic medication and clinical symptomatology was
exploratory and not corrected for multiple comparisons.
Conclusions
In summary, these data suggest a partially overlapping
pattern of elevated inflammatory cytokines in patients
with first-episode schizophrenia and bipolar disorder.
Furthermore, our findings suggest that higher levels of
these pro-inflammatory cytokines likely play an import-
ant role in schizophrenia pathophysiology, particularly
given the evidence of cytokine-related decreases in per-
cent whole-brain gray matter. The field could clearly
benefit from future studies that test the use of adjunctive
anti-inflammatory treatments as well as the use of per-
ipheral biomarkers to identify “immune-vulnerable” sub-
groups of individuals who may benefit the greatest from
this treatment. Finally, the role of antipsychotic medica-
tions and episodic changes in cytokine levels requires
further study to understand the course of inflammation
in individuals with affective and non-affective psychosis.
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